Vertex (VRTX) volatility flat as shares rally 54% on improved lung function treatement

Vertex (Nasdaq: VRTX) is recently up $20.35 to $57.76 after the company reported better than expected data from the Phase II trial of KALYDECO + VX-809 in cystic fibrosis patients. RBC Capital Markets raised its price target to $63. June call option implied volatility is at 48, July is at 54; compared to its 26-week average of 52.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BJ's Wholesale Club (BJ) call put ratio 1.3 calls to 1 put into quarter results
• SpaceX (SPCX) call put ratio 1.5 calls to 1 put as share price up 1.4%
• Oracle (ORCL) October 175 calls active as share price up 3.6%